Scorpion Therapeutics in the up to $2.5 billion pending sale of the PI3Kα inhibitor program, a treatment for breast cancers in clinical trials, to Eli Lilly and Company (NYSE: LLY)
CCC Intelligent Solutions in its $730 million acquisition of EvolutionIQ, a provider of a platform for AI-powered guidance for disability and injury claims management
Integrated Oncology Network, a provider of oncology services, in its $1.115 billion sale to Cardinal Health (NYSE: CAH)
GTCR-backed Cloudbreak Health in its acquisition of Voyce, a provider of language interpretation services
Commure, a General Catalyst portfolio company, in its take-private acquisition of Augmedix
Monarch Alternative Capital-backed Shopko Optical, an optical retailer and provider of optometric services, in its $290 million sale to Fielmann Group
Peak Rock Capital in its $787.5 million acquisition of HuFriedyGroup, a provider of instruments, infection prevention products, instrument management systems and conscious sedation products for the dental industry, from STERIS
Knox Lane in its acquisition of All Star Healthcare Solutions, a healthcare staffing firm focused on the locum tenens market
GTCR-backed RevSpring, a provider of communication and payment solutions, in its sale to Frazier Healthcare Partners
CapVest Partners-backed Calyx in its $115 million acquisition of Invicro, a provider of imaging biomarker services, from REALM IDx
MB2 Dental on a $2.344 billion unitranche debt facility with credit vehicles and accounts managed by KKR
